Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Bradpalm1 who wrote (10676)	11/12/1998 10:27:00 PM
From: Andrew H	Read Replies (1) \| Respond to of 119973

It was a bit of a black humor, Scott. Anyone who remembers the thalidomide baby horrors knows what I was referring to. But as you say, many new and exciting uses for thalidomide are now being discovered, anti-angiogenesis among them. I understand it has been in testing for AIDS, as well, and I think I heard something about leprosy at one point? Anti-angiogenesis is certainly a major new hope in the fight against cancer, and I am very pleased to hear about the success of the AGPH drug. You say P 11/111--are they pivotal trials? Or would they have to do an additional P3 as well? Probably depends on the results. The WSJ article certainly raised a lot of questions, and you are right that they will take months to answer. Of course we all hope that the results with mice can be replicated in humans, but the odds are quite long. We shall see. Do you ever check in on the VD thread? They have some good biotech discussions. Several medical professionals and people with experience in the field participate.